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Abstract 
Background: Lithium has been used clinically for 70 years, mainly to treat bipolar disorder. Competing treatments 
and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some 
countries, encouraging this update about its safe clinical use. We conducted a nonsystematic review of recent 
research reports and developed consensus among international experts on the use of lithium to treat major mood 
disorders, aiming for a simple but authoritative guide for patients and prescribers.
Main text: We summarized recommendations concerning safe clinical use of lithium salts to treat major mood dis‑
orders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including 
during pregnancy and for the elderly.
Conclusions: Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, espe‑
cially for long‑term prophylaxis.
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Historical introduction
In 1949, John Cade (1929–1996), an Australian psychia-
trist, serendipitously initiated a new era in psychiatric 
treatment by using lithium carbonate to treat mania. 
His use of lithium arose from the hypothesis that major 
mental illnesses might be associated with deficiencies 
or excesses of unidentified chemical substances, includ-
ing accumulations of nitrogenous metabolites. This idea 
led him to give lithium carbonate to laboratory animals 
to limit toxicity of test substances including uric acid and 
noting calming and other behavioral changes. Subse-
quently, he reported on beneficial effects of treating ten 
patients with lithium carbonate (a medically accepted, 
though unproved, treatment for gout) for mania and 
on risks of discontinuing such treatment (Cade 1949). 
These encouraging initial results are now widely consid-
ered a revolutionary discovery, although this innovative 
and effective treatment was not immediately adopted 
by psychiatry. As Cade himself observed, “a discovery 
by an unknown psychiatrist without research training, 
working in a small hospital for the chronically mentally 
ill, with primitive techniques and negligible equipment, 
could not attract much attention” (Cade 1999). In addi-
tion, several cases of severe, acute intoxication associ-
ated with use of lithium salts as a substitute for table salt 
(sodium chloride) were reported in 1949, and some expe-
rience was required to learn how to use lithium safely. 
This could be achieved by measuring its concentration in 
blood (Amdisen 1967; Baldessarini 2013; Bauer and Git-
lin 2016).
In 1954, Professor Erik Strömgren (1909–1993), a 
prominent academic psychiatrist at the University of 
Aarhus Medical Center in Denmark, read of Cade’s 
experience with lithium for mania and asked his then-
junior colleague Mogens Schou (1918–2005) to repli-
cate the Australian findings. Schou not only did so but 
pursued the study of lithium to contribute in a major 
way to establishing its safe and effective clinical use for 
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the treatment of manic-depressive illness. His research 
in collaboration with another Danish psychiatrist, Poul 
Baastrup (1918–2001), established the most important 
effect of lithium—its ability to prevent recurrences of 
manic-depressive illness (Baastrup 1964; Baastrup and 
Schou 1968). In Zurich, Jules Angst (born 1926) and 
his collaborators confirmed the prophylactic benefits 
of lithium treatment (Angst et  al. 1970). In addition, 
Angst with Paul Grof (born 1935) and other colleagues 
proposed methods of clinical trial-design suitable for 
testing for long-term, prophylactic effects of a treat-
ment such as lithium (Grof et al. 1970).
Gradually lithium became accepted in clinical prac-
tice around the world, though not without some resist-
ance. There was, in fact, a strong skepticism about its 
long-term efficacy, based on reasonable considerations 
(Blackwell and Shepherd 1968). These included the 
requirement for evidence from blinded, randomized, 
controlled trials. The first of these helped to con-
vince the scientific and clinical community (Baastrup 
et al. 1970). Lithium treatment finally received regula-
tory approval by the US Food and Drug Administra-
tion (FDA) in 1970 for treatment of acute mania, and 
in 1974 as the first—and for many years, the only—
approved treatment for prevention of recurrences in 
bipolar disorder. In addition to its potentially toxic 
effects, lithium being an unpatentable natural prod-
uct with limited commercial interest had difficulties 
in attracting extensive support for research or clinical 
promotion by pharmaceutical corporations.
Clinical applications of lithium were made feasible 
by introducing sensitive, reliable, quantitative meth-
ods of monitoring lithium concentrations in serum, 
initially with flame spectrophotometry and later with 
atomic absorption, electrochemical, and other detec-
tion methods. These established circulating concentra-
tions of lithium required for safe and effective clinical 
dosing (Amdisen 1967; Bauer and Gitlin 2016). Such 
monitoring was required because of the narrow mar-
gin between the safe and potentially toxic dose of lith-
ium, or its “therapeutic index” (ratio of median toxic 
to therapeutically effective doses, of approximately 3) 
(Baldessarini 2013; Bauer and Gitlin 2016; Perugi et al. 
2019). Indeed, lithium remains unique in not being 
dosed adequately by the mg dose of drug given per 
day, but instead by achieving serum concentrations 
10–14 h after the last taken dose (most stable range of 
the day) on the range of 0.5–1.0  mEq/L, while being 
aware that earlier, daily peak concentrations can be 
2–3-times higher (Amdisen 1967; Baldessarini 2013; 
Bauer and Gitlin 2016; Perugi et al. 2019).
Lithium today
Lithium treatment remains the “gold standard” of treat-
ment for preventing recurrences in bipolar disorder, 
both types I (with mania and major depression) and 
II (with depression and hypomania). It also has evi-
dence of effectiveness for preventing suicidal behavior 
in patients with bipolar or major depressive disorder. 
However, it has gradually become less widely utilized, 
particularly for mania, mainly due to more vigorously 
promoted and more rapidly effective alternatives which 
do not require blood tests. These alternatives include 
drugs developed for other purposes, including cer-
tain anti-epilepsy agents (carbamazepine, lamotrig-
ine, sodium valproate) and most antipsychotics. Their 
adverse effects include metabolic syndrome (weight-
gain with diabetes, high blood pressure, and increased 
lipids in the blood), insulin resistance, abnormal move-
ments, and cognitive dulling with antipsychotics, as 
well as markedly increased risks of birth defects includ-
ing spina bifida and severe cardiac anomalies during 
pregnancy in association with valproate and carbamaz-
epine (Patel et  al. 2018). Concerns about the safety of 
lithium have not entirely disappeared, despite long-
established standards for its safe use with monitoring of 
its serum concentrations.
Fears about lithium treatment currently are most often 
directed to putative renal toxicity with its long-term use. 
In fact, such effects are uncommon and usually can be 
anticipated by rising serum concentrations of creatinine 
or declining creatinine clearance (McKnight et  al. 2012; 
Baldessarini 2013; Bauer and Gitlin 2016; Haussmann 
et al. 2017; Perugi et al. 2019). This adverse effect of lith-
ium is modest, and greatly overlaps with age-associated 
declining renal function (Nielsen et  al. 2018). An indi-
cation of declining renal function (at least one elevated 
serum concentration of creatinine) was documented in 
about 30% of subjects treated with lithium for 15 years or 
more and aged 55 years or older (Tondo et al. 2017).
Some patients and families may feel that lithium treat-
ment has a “stigmatizing” effect, as lithium is perceived 
as a medication for severely ill patients, in contrast to 
seemingly less stigmatizing anticonvulsant, antidepres-
sant, antipsychotic and other psychotropic medicines 
(Baldessarini 2013; Bauer and Gitlin 2016). In some 
countries, particularly in the US, vigorous promotion of 
alternative and patented treatments, sometimes more 
rapidly acting against mania, have led to substantial dis-
placement of lithium for acute mania. Nevertheless, 
lithium continues to hold a major position among treat-
ments for bipolar disorder internationally, especially for 
long-term prophylactic treatment, and it tends to be used 
for longer times than most alternatives (Baldessarini et al. 
2007, 2008, 2019b).
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Efficacy of lithium treatment
Although lithium is effective in treating acute manic 
episodes, its primary value is as a “mood-stabilizing” 
agent, aiming at long-term prevention of recurrences 
of acute illness-episodes in bipolar disorder patients 
(Baldessarini 2013; Bauer and Gitlin 2016; Haussmann 
et al. 2017; Malhi et al. 2017; Perugi et al. 2019), with 
greater benefit against recurrences of mania than for 
bipolar depression (Kleindienst and Greil 2000), as 
the case also with alternative treatments (Baldessarini 
2013; Forte et  al. 2015). Satisfactory mood-stabiliza-
tion over 6–12 months can be attained by about two-
thirds of lithium-treated bipolar disorder patients, 
and an excellent response (e.g., 3 years with no recur-
rences) has been found in one-third of such patients 
(Grof 2006). Recent comprehensive reviews consid-
ered the benefits of various proposed mood-stabilizing 
treatments, including lithium, against recurrences of 
mania and depression in bipolar disorder patients, in 
more than a dozen placebo-controlled, randomized, 
long-term trials carried out for an average of 1.5 years 
(Geddes et  al. 2004; Popovic et  al. 2011, 2012: Vieta 
et al. 2011; Miura et al. 2014). Such studies found that 
long-term risk of new manic or depressive episodes 
was lower with lithium than with placebo, although 
the benefit was greater against new episodes of mania 
than of depression. Indeed virtually all available treat-
ments for bipolar disorder, including lithium, anti-
convulsants, and antipsychotics are notably limited in 
their effectiveness against recurrences or acute epi-
sodes of bipolar depression and their long-term recur-
rences, with the exception of lamotrigine for long-term 
treatment (Geddes et al. 2004, 2010; Poon et al. 2012; 
Baldessarini 2013; Vázquez et  al. 2013; Forte et  al. 
2015). However, some randomized, double-blind tri-
als from the 1970s and several recent studies found 
that long-term treatment with lithium also may reduce 
recurrences in unipolar major depressive disorder 
(Abou-Saleh et  al. 2017; Tiihonen et  al. 2017; Undur-
raga et  al. 2019). In addition, lithium appears to have 
value in augmenting antidepressant treatment, espe-
cially during episodes of unipolar major depression 
that respond unsatisfactorily to antidepressant treat-
ment. Most studies supporting this application have 
involved older, tricyclic antidepressants, but similar 
effects may occur with modern antidepressants as well 
(Austin et  al. 1991; Bauer and Döpfmer 1999; Bauer 
et al. 2003; Alevizos et al. 2012; Bauer and Gitlin 2016; 
Undurraga et  al. 2019). Finally, it has been suggested 
that lithium occurring naturally in drinking water may 
lower the incidence of dementia, but this finding needs 
to be verified (Kessing et al. 2017a, b).
Differential response to lithium
Mood-stabilizing and prophylactic benefits of lith-
ium may be particularly evident in patients with typi-
cal bipolar disorder that includes an episodic clinical 
course before treatment, a family history of the disor-
der and favorable response by a family member, lack of 
other co-occurring psychiatric illnesses, and an illness 
course-sequence characterized by mania or hypomania 
followed by depression and then a stable or euthymic 
interval (“MDI” pattern) rather than the opposite 
(depression-mania-euthymic interval (“DMI”)) (Kouk-
opoulos et  al. 2013; Malhi et  al. 2017; Yatham et  al. 
2018). In particular, patients with an MDI course-type 
(especially likely in type I bipolar disorder) have shown 
a 29% (CI 18–40%) better response to lithium than 
those with a DMI course (more likely in type II bipo-
lar disorder and often triggered by overuse of antide-
pressants) (Kukopulos et  al. 1980; Koukopoulos et  al. 
2013). This association with the type of illness-course 
is consistent with the view that depression-prone bipo-
lar disorder patients, generally, respond less favorably 
to treatment than mania-prone patients (Vieta et  al. 
2009; Baldessarini et  al. 2012). Of interest, both the 
DMI versus MDI recurrence pattern, as well as the 
tendency to a long-term excess of mania over bipolar 
depression may be identifiable very early on the illness 
history, possibly from the first-lifetime episode or cycle 
(Baldessarini et al. 2012; Koukopoulos et al. 2013; Forte 
et al. 2015).
Responsiveness to lithium (and alternative treat-
ments) has been inferior among patients with rela-
tively complicated forms of bipolar disorder, such as 
with rapid-cycling, psychotic features, co-occurring 
anxiety syndromes or substance-abuse, as well as in 
depression-prone cases or those following the DMI 
course pattern, and lithium is less effective in pre-
venting recurrences of bipolar depression than mania. 
Importantly, the same limitations hold true for alterna-
tive treatments, including anticonvulsants and mod-
ern antipsychotics (Baldessarini et  al. 2002;  Tondo 
et  al. 2003; Bauer and Gitlin 2016), and no alternative 
treatment appears consistently to outperform lithium 
for long-term maintenance treatment (Geddes et  al. 
2004, 2010; Baldessarini 2013; Pacchiarotti et  al. 2013; 
Vázquez et al. 2013; Bauer and Gitlin 2016; Malhi et al. 
2017; Yatham et  al. 2018). Moreover, as for all main-
tenance treatments, a favorable clinical response is 
associated with faithful adherence to the treatment 
regardless of current lack of symptoms, absence of early 
or current adverse life events, adult age at onset, good 
social support, and absence of substance abuse or other 
co-occurring psychiatric disorders including personal-
ity disorders (Yatham et al. 2018).
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Starting and discontinuing treatment and medical 
monitoring
Whether indefinitely continued maintenance treatment 
should be started routinely after an initial manic epi-
sode lacks clear consensus. A conservative view would 
initiate long-term treatment after a second episode of 
mania since the first might be followed by another only 
after several years or may be of only moderate sever-
ity and duration. Typically, patients are continued on 
lithium or an alternative treatment for at least some 
months following recovery from an acute episode of 
mania or bipolar depression, with reassessment of the 
need to continue thereafter. Lithium probably should 
be started after a first manic episode presenting with 
severe symptoms, required hospitalization, or involved 
suicidal risk or prolonged duration. In general, early 
long-term intervention and follow-up are encouraged 
after a manic episode, and especially of juvenile onset, 
because of the adverse impact of bipolar illness on a 
patient’s educational, occupational, and social func-
tioning (Kessing et al. 2017a, b).
Because of the frequent lack of timely recognition 
and diagnosis of bipolar disorder, especially of type II, 
initiation of long-term treatment with lithium or other 
mood-stabilizing treatments typically does not occur for 
5–10 years from illness-onset, and even longer following 
juvenile onset (Post et  al. 2010; Kessing et  al. 2017a, b). 
Such delay, with associated morbidity, contribute con-
siderably to disability and risk of suicide. Nevertheless, 
some studies have found that neither such delays nor the 
number of recurrences before treatment had a measur-
able impact on the likelihood of responding once mood-
stabilizing treatment was initiated (Baethge et  al. 2003; 
Bratti et al. 2003; Berghöfer et al. 2008).
Before starting treatment with lithium, and once or 
twice a year thereafter, we recommend measuring blood 
concentrations of (a) creatinine and urea-nitrogen (BUN) 
to evaluate kidney function, (b) sodium, potassium, cal-
cium, and (c) thyroid and parathyroid hormones, as well 
as obtaining an electrocardiogram—all of which can be 
affected by lithium.
Discontinuing long-term lithium treatment of mood 
disorder patients leads to a substantial risk of illness-
recurrences, need for hospitalization, and of suicidal 
behavior, especially if the discontinuation is rapid or 
abrupt. The risk is especially high in the 6–12  months 
after discontinuation (Faedda et  al. 1993; Baldessarini 
and Tondo 2019). Of note, recurrences of bipolar dis-
order following discontinuation of maintenance treat-
ment may be more severe and occur much sooner when 
lithium is discontinued rapidly (< 15  days) or abruptly 
(Faedda et  al. 1993; Baldessarini 2013). This effect not 
only reflects lack of treatment but may be a response 
to treatment-discontinuation itself as a major stressor 
(Baldessarini and Tondo 2019).
Lithium and suicide
Patients with bipolar disorder have an increased stand-
ardized mortality ratio (SMR) for all-cause mortality as 
compared to the general population, with higher rates 
of suicide at young ages and of fatal medical illnesses in 
late years (Ösby et  al. 2001; Staudt-Hansen et  al. 2019). 
SMR for suicide as the cause of death is far higher with 
bipolar disorder and severe, recurrent, non-bipolar major 
depression (especially involving psychiatric hospitaliza-
tion) than other psychiatric disorders, up to 20-times 
higher than the international general population rate 
of approximately 15/100,000/year (0.015%/year) (Har-
ris and Barraclough 1997; Ösby et  al. 2001; Simon and 
Hales 2012; Baldessarini et al. 2019a, b, c). This excess of 
mortality is strongly associated with suicide in younger 
patients, but with co-occurring medical disorders in 
older patients (Ösby et al. 2001; Baldessarini et al. 2019a). 
Suicide is far more likely in depressive, and especially 
dysphoric-agitated or mixed, phases of bipolar disorder 
than in manic periods, and is rare in hypomania (Swann 
et al. 2013; Tondo and Baldessarini 2016). The rate of sui-
cide attempts is at least 20–30 times greater than rates of 
suicide in the general population but the ratio of suicides/
attempts is much lower among patients with a major 
mood disorder (≤ 10). This ratio indicates greater lethal-
ity of means and intent in major mood disorder patients 
with a similar risk of suicidal behavior in types I and II 
bipolar disorder (Tondo et al. 2016).
Initial considerations that lithium treatment might 
contribute to suicide prevention date to the early 1970s 
(Barraclough 1972), followed by important contributions 
supporting this hypothesis over the next two decades 
(Coppen et al. 1991; Coppen and Farmer 1998). An early 
case–control study of suicidal risk in 68 patients with 
various major affective disorder diagnoses and at least 
one suicide attempt, found a rate of suicides or attempts 
during 8.0 years of lithium treatment of 1.1%/year, with 
a highly significant increase to 2.0%/year following dis-
continuation of lithium treatment (Müller-Oerling-
hausen et  al. 1992). In 360 type I or II bipolar disorder 
patients before, during, and following discontinuation 
of long-term lithium monotherapy, rates of suicide and 
life-threatening attempts were 6.4-times lower during 
lithium-treatment than either before (only attempts) or 
long after treatment. The risk of suicidal acts increased 
20-fold within several months after discontinuing lithium 
maintenance treatment, but later fell back to the same 
level encountered before lithium treatment had started 
(Tondo et al. 1998). Moreover, early suicidal risk follow-
ing discontinuation of long-term treatment with lithium 
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was twice-higher following abrupt or rapid versus more 
gradual discontinuation of lithium over at least 2-weeks.
In a systematic review of 12 studies, the pooled rate 
of suicides and attempts was 8.9-times lower with lith-
ium treatment (p < 0.0001) (Tondo et  al. 2001). In addi-
tion, a review of 8 studies on unipolar recurrent major 
depression patients found that long-term lithium treat-
ment was again associated with a substantial reduction 
of risk of suicides and attempts (by approximately 76%) 
among patients treated with lithium compared to other 
alternatives, mainly antidepressants and anticonvulsants 
(Guzzetta et al. 2007). Similar effects on suicidal behavior 
have not been achieved with several proved or putative 
mood-stabilizing anticonvulsants (including carbamaz-
epine, lamotrigine, and valproate) (Thies-Flechtner et al. 
1996; Goodwin et al. 2003; Baldessarini et al. 2009; Smith 
et al. 2009). Antipsychotic drugs have not been tested for 
such effects in bipolar disorder patients. An association 
of reduced suicidal risk during long-term treatment with 
lithium in bipolar disorder patients is supported by sev-
eral studies and quantitative reviews (Angst et  al. 2005; 
Cipriani et  al. 2005, 2013; Kessing et  al. 2005; Müller-
Oerlinghausen et al. 2006; Lauterbach et al. 2008; Lewit-
zka et  al. 2013). It may be that an antisuicidal effect of 
lithium treatment is at least partly independent from its 
mood-stabilizing effect (Ahrens and Müller-Oerling-
hausen 2001; Manchia et al. 2013). If so, patients achiev-
ing only a partial clinical response to lithium treatment 
might still benefit from its antisuicidal effects (Ahrens 
and Müller-Oerlinghausen 2001).
Overall, the findings summarized here, appear to pro-
vide strong and quite consistent support for the hypoth-
esis that lithium treatment may have a special role in 
reducing suicidal risks. Although these findings are 
encouraging and unusual, it must be emphasized that 
such an effect of lithium treatment has not yet been 
definitely proved in prospective, randomized trials in 
which suicidal behavior is an explicit outcome. Largely 
for that reason, lithium has not been accepted by the 
FDA as a specific indication to prevent suicidal idea-
tion or behavior. Such an indication was requested in a 
citizen’s petition to FDA by Drs. Frederick Goodwin and 
Ross J. Baldessarini. This included data from several ran-
domized, controlled trials in which suicidal acts were 
cited as adverse outcomes. However, no pharmaceutical 
company is likely to underwrite studies or to make for-
mal application to the FDA for such an indication. The 
only randomized and controlled study in patients who 
have attempted suicide, with suicidal behavior as an 
explicit outcome, found a significantly lower number of 
suicides in the lithium group compared to placebo (0 vs. 
3 suicides; p = 0.049) but not in the number of suicide 
attempts (7 vs. 10 attempts) (Lauterbach et al. 2008).
Lithium dosage and blood concentration
The following guidelines for managing lithium treatment 
are based on several recent publications and the exten-
sive clinical experience of the authors (Baldessarini 2013; 
Bauer and Gitlin 2016; Haussmann et  al. 2017; Malhi 
et al. 2017; Perugi et al. 2019). As noted, lithium is used 
mostly as a long-term treatment to prevent mood-disor-
der recurrences. Its place in the treatment of acute mania 
has largely been displaced in favor of some anticonvul-
sants and modern antipsychotic drugs, which act more 
rapidly and whose target doses can be reached within a 
few days. In particular, the most common current treat-
ment for a manic episode is with modern antipsychotic 
agents for several months, with lithium introduced 
adjunctively or continued long-term by itself as a preven-
tive treatment (Yatham et al. 2018).
Lithium should be taken regularly as prescribed. A 
daily single dose after the evening meal is convenient, 
preferably with slow-release formulations in relatively 
young, otherwise healthy patients. This practice can sup-
port critically important, long-term treatment-adherence 
(Malhi et al. 2017). For older or infirm patients, and users 
of high daily doses (over 1200  mg of lithium carbonate 
[32 mEq]), divided daily doses may be safer. If a dose is 
missed it is not safe to double the next dose. If the brand 
or salt-form of lithium needs changing, this should be 
done by gradually discontinuing the first preparation as 
the second is introduced and gradually increased. The 
optimum amount of lithium to be taken is based on clini-
cal response and measured blood levels of lithium which 
guide the dose of lithium. Blood assays of lithium usually 
are obtained at 1  week after the start of lithium treat-
ment, then monthly in the first 3 months. Subsequently, 
when the patient is considered stable, blood tests may be 
done every 6  months depending on age, general health, 
and response to treatment. Blood should be drawn at a 
consistent interval, at 10–14 (optimally, 12) hours after 
the last intake. If a dose is changed, 5–7 days should pass 
before measuring the blood level to allow tissue distribu-
tion to stabilize. Optimal doses of lithium are decided 
by a clinician, and depend on the patient’s age, general 
health, type of bipolar disorder, symptom-severity, and 
frequency of recurrences. Optimal daily trough blood 
concentrations of lithium for long-term treatment usually 
are between 0.50 and 0.60 and 0.80–1.00  mEq/L. Some 
patients may require higher concentrations, whereas for 
others, lower concentrations may suffice and better tol-
erated. For example, higher serum levels of lithium may 
be required for young patients with severe manic or psy-
chotic symptoms (delusions, hallucinations) or patients 
with short intervals between episodes, whereas lower 
concentrations are often used and better tolerated by 
elderly patients.
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Lithium dose is best decreased by half or held for some 
days in cases with fever above 38 °C (100.4 °F), dehydra-
tion or diarrhea. Lithium also should be taken with extra 
caution during treatment with certain medicines that 
can slow its renal elimination and increase risk of toxic 
effects, and if a low-sodium diet is required for medical 
reasons. Such drugs include the commonly used non-
steroidal anti-inflammatory drugs (NSAIDs) such as 
ibuprofen or nimesulide if they need to be taken more 
than occasionally. Lithium blood level measurements 
are recommended if such drugs are taken regularly for 
extended periods. However, a safer treatment for pain 
or fever than an NSAID is acetaminophen/paracetamol. 
Certain anti-hypertensives (notably angiotensin-convert-
ing enzyme [ACE] inhibitors), some drugs used to treat 
cardiac arrhythmias, and most diuretics should be used 
with caution. During use of lithium with any of these 
medicines, serum lithium levels may rise and should be 
monitored frequently. In addition, lithium treatment 
should be stopped 48–72 h before surgery that requires 
general anesthesia, and while a patient does not drink or 
eat as usual. For surgeries requiring local anesthesia, no 
interruption is needed. Lithium may be resumed when 
the patient is well hydrated (Huyse et  al. 2006). Finally, 
lithium should be stopped during electroconvulsive 
treatment (ECT) as a precaution to prevent possible neu-
rological symptoms (delirium) (Tsujii et al. 2019).
Adverse effects and contraindications
Some adverse effects are common during treatment with 
lithium. These include tremor (a dose-dependent effect, 
which can be treated with low doses of the centrally 
active, beta-adrenergic blocker propranolol, high doses 
of vitamin B6, or with dose reduction if possible), nau-
sea, fatigue, increased appetite, increased white blood-
cell count, thirst, and increased frequency of urination 
(polyuria). This symptom may respond to cautiously 
added, small doses of the diuretic hydrochlorothiazide 
(which can also increase serum concentrations of lith-
ium and decrease potassium). Some patients complain 
of decreased cognitive functions. Some of these adverse 
effects (especially thirst and tremor) tend to disappear 
over the first weeks of treatment. Gastro-intestinal com-
plaints may be lessened by switching to another lithium 
preparation. Hypothyroidism is also possible and usually 
is treated with supplemental thyroid-hormone (Ambro-
siani et  al. 2018; Bocchetta et  al. 2018). Hyperparathy-
roidism and consequent hypercalcemia can also arise 
during long-term treatment with lithium (Twigt et  al. 
2013).
Lithium should not be used by patients who have or 
have had: acute myocardial infarction, acute kidney fail-
ure, or certain rare disorders of heart rhythm (notably, 
the Brugada syndrome of ventricular arrhythmia). Lith-
ium can be used cautiously and with close medical moni-
toring in the presence of: cardiac arrhythmia, reduced 
kidney function, psoriasis, myeloid leukemia, Addison’s 
disease, hypothyroidism, and certain neurological dis-
orders, including abnormalities of posture and move-
ment, myasthenia gravis, and epilepsy. A rare, probably 
irreversible, syndrome acronymized as SILENT (Syn-
drome of Irreversible Lithium-Effectuated Neurotoxicity) 
involving persisting cerebellar dysfunction with ataxia or 
unsteady gait has been reported in a few cases (Aditanjee 
et al. 2005).
In older patients, doses of lithium should be about 20% 
lower than those for younger patients, as determined by 
the attending clinician (Shulman et  al. 2019). Common 
adverse effects in the elderly, in addition to those already 
described, can include: confusion or worsening of cogni-
tive functions, unsteady balance and gait (ataxia), restless 
movements (akathisia), declining kidney function, hypo-
thyroidism, possible worsening of diabetes mellitus, and 
leg-swelling (peripheral edema).
Abnormally high blood levels of lithium (above 
1.5  mEq/L) can increase risk of intoxication, signs of 
which are severe tremor, confusion, vomiting, abdomi-
nal pain, diarrhea, abnormally increased reflexes, speech 
difficulties, abnormal heart rhythm, hypotension, and 
convulsions. The prescribing clinician or an emergency 
service should be consulted immediately if such symp-
toms occur. Blood tests to determine the level of lithium 
is required. If it is very high (above 2 mEq/L), blood dial-
ysis may be needed to remove lithium—a decision best 
made in consultation with a kidney specialist. Even if 
measured blood levels lithium are not greatly elevated, 
intoxication may be present due to circulating levels in 
blood not being in equilibrium with those in the central 
nervous system, and lithium should be stopped as clinical 
evaluation is pursued.
Lithium in pregnancy and post‑partum
Use of lithium in pregnancy has long been a matter of 
discussion. In the past, the mainstream opinion was 
that lithium should be discontinued immediately when 
pregnancy was ascertained or planned. The major con-
cern was risk of a rare congenital cardiac abnormality 
(Ebstein’s anomaly, arising in approximately 1 in 20,000 
live births without lithium exposure). Recent studies 
have confirmed the association between maternal expo-
sure to lithium in the first 3  months of pregnancy and 
increased risk of this and other fetal malformations but 
their risk-estimates are lower than previously reported 
(Patorno et al. 2017; Munk-Olsen et al. 2018; Poels et al. 
2018). Reduction of lithium doses during the first trimes-
ter may be considered but weighed against the especially 
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high risks of relapse (especially of depressive or mixed 
states of bipolar disorder) early in pregnancy associated 
with treatment discontinuation (Viguera et  al. 2007). 
When lithium is prescribed during pregnancy, serum 
concentrations should be monitored frequently (at least 
monthly), and preferably weekly in the third trimester 
(Wesseloo et al. 2017). It is not necessary to stop lithium 
before delivery, but blood levels should be measured 
twice weekly for the first 2 weeks after delivery (Wesseloo 
et al. 2017). If delivery is prolonged, it is vital to ensure 
a good fluid intake during treatment with lithium. Cli-
nicians and patients should discuss risks and benefits of 
continuing, lowering, or interrupting lithium treatment 
in anticipation of pregnancy and after childbirth, includ-
ing during breast-feeding (Poels et al. 2018).
If lithium is discontinued during pregnancy in a 
woman with bipolar disorder, it should be restarted 
immediately after delivery, because the early post-par-
tum period carries a high risk for recurrences of bipolar 
disorder and depression (Viguera et  al. 2007; Wesseloo 
et  al. 2016). Serum lithium levels are often increased 
to 0.8–1.0  mEq/L during the first month after child-
birth to minimize risk of illness and checked at least 
weekly for a month. If the blood level is stable, it can 
be checked monthly for the next 3–6  months. Breast-
feeding during lithium treatment is not recommended 
Table 1 Recommendations for patients treated with lithium and their prescribers
Background Lithium salts (carbonate, citrate, or sulphate) have been widely used for about 70 years to treat illnesses characterized by periods of depres‑
sion and elevated or excited mood (bipolar disorder) or with depression only (major depressive disorder). Lithium and other mood‑stabilizing treat‑
ments do not cure mood disorders but can reduce the frequency, severity, and duration of relapses and improve long‑term stability
Indications Lithium is especially effective in preventing recurrences of excited (manic) mood and can also reduce the risk of depressive recurrences. It is 
the only medicine with evidence of reducing risk of suicidal behavior associated with mood disorders. It may also reduce risk of cognitive decline in 
the elderly
Dosing Lithium should be taken regularly, exactly as prescribed. If a dose is missed, do not double the next dose. A single daily dose is sometimes used 
and more convenient than divided doses. Changing the brand or type of lithium salt used may require dosage re‑adjustment with supervision by 
your doctor
Blood concentrations of lithium Measuring the blood level of lithium is very important. It should be done about 1 week after the first dose, then weekly 
in the first month, at least once a month in the next 3–6 months, and every 3–6 months thereafter. Blood sampling should be done reliably at a 
consistent interval (optimally about 12 h after the last dose of the day) and about a week after any dose change. Prescribed dosing is guided by blood 
concentrations of lithium decided by your doctor, usually at 0.50–0.80 mEq/L
Factors that can alter blood levels Talk with your doctor about lowering your daily dose of lithium or to discontinue temporarily with: fever above 38 °C 
(100.4 °F), dehydration or diarrhea, or when a low sodium diet is required (not recommended during lithium therapy). Long‑term use of nonsteroidal 
anti‑inflammatory drugs (NSAIDs) is not recommended with lithium (acetaminophen/paracetamol is preferred for pain). ACE‑inhibitors, some cardiac 
antiarrhythmics, and thiazide‑diuretics should not be used with lithium
Other blood tests Blood levels of creatinine (for kidney function), sodium, potassium, calcium, thyroid and parathyroid hormones should be measured 
before starting the treatment and at least, once or twice a year thereafter
Adverse effects Nausea, thirst, tremor, fatigue, decreased cognitive functions, increased appetite, increased frequency of urination. These are most often 
encountered early in treatment and usually improve with time, but may require additional treatments
Use in medical conditions Lithium should not be used by patients who have or have had: acute myocardial infarction (heart attack), acute kidney failure, 
or certain rare disorders of heart rhythm. It can be used cautiously and with close medical monitoring with: cardiac arrhythmia, reduced kidney func‑
tion, psoriasis, myeloid leukemia, Addison’s disease, hypothyroidism, and certain neurological disorders, including abnormalities of posture and move‑
ment, tremors, myasthenia gravis, and epilepsy. Lithium should be stopped 48–72 h before surgery requiring general anesthesia, and during periods 
of low fluid intake. Ask your doctor before taking new medicines
Use in the elderly At ages over 60 years, doses and blood levels of lithium are at the low end of the therapeutic range (e.g., 0.4–0.6 mEq/L). Undesirable 
effects in the elderly in addition to those already described can include: confusion or worsening of cognitive functions, unsteady balance (ataxia), 
restless movements (akathisia), declining kidney function, hypothyroidism, possible worsening of diabetes, and leg‑swelling (peripheral edema)
Pregnancy Lithium is used cautiously in pregnancy, with at least monthly monitoring of blood concentrations. If possible, lithium should be discon‑
tinued slowly or the dose lowered during the first trimester because of the association between lithium use and congenital malformations (birth 
defects) in this early period. Discuss risks and benefits of continuing, lowering, or interrupting lithium treatment during pregnancy and after childbirth 
with your doctor. During the third trimester, lithium blood levels should be monitored weekly. It is not necessary to stop lithium before delivery
Postpartum If lithium is discontinued during pregnancy, it should be restarted immediately after delivery, due to increased risk of relapses then. Target 
lithium levels should be relatively high (0.8–1.0 mEq/L) temporarily during the first month after delivery to minimize relapse risk, and checked twice 
weekly during the first 2 weeks after delivery. Do not breast‑feed while taking lithium
Lithium intoxication Signs of high lithium blood levels include: severe tremor, confusion, vomiting, abdominal pain, diarrhea, speech difficulties, cardiac 
arrhythmia, hypotension, and convulsions. Some signs of intoxication may occur despite normal plasma levels of lithium. If the blood level of lithium 
is above 2 mEq/L, dialysis may be needed to remove lithium. Call your doctor or an emergency number immediately on suspicion of lithium intoxica‑
tion
Discontinuation Interrupting lithium should be done gradually and under medical supervision to avoid relapse into mania or depression, unless an 
acute medical problem requires rapid discontinuation under close medical supervision. Dose‑reduction of lithium can be done safely by lowering the 
daily dose by 20–25% every 2 weeks
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(as concentrations in breast milk are about half of the 
concentrations in maternal blood), and infant feeding 
formula should be used (Galbally et al. 2018; Poels et al. 
2018).
Whenever lithium is discontinued, this should be done 
gradually, over at least a month at a rate of dose-reduc-
tion of 20–25% every 2 weeks or longer. If an acute medi-
cal problem requires rapid discontinuation, this needs to 
be carried out under close medical supervision.
Conclusions
In addition to publications cited above (Baldessarini 
2013; Bauer and Gitlin 2016; Baldessarini et al. 2019a, b, 
c; Perugi et al. 2019), several helpful guidelines concern-
ing bipolar disorder and its treatment have appeared 
in recent years (Licht et  al. 2003; Goodwin et  al. 2016; 
Grunze et al. 2013; Fountoulakis et al. 2017; Haussmann 
et al. 2017; Malhi et al. 2017; Nederlof et al. 2018; Yatham 
et al. 2018). These publications may not be readily avail-
able to many physicians working outside of large aca-
demic or clinical institutions. Moreover, many patients 
rely on information from the internet, which may be 
unreliable. These circumstances led us to prepare of this 
report, which aims to provide a brief and accessible but 
expert overview for patients, their caregivers (parents, 
spouses, children, siblings, or friends), and their doctors. 
Key points are summarized in Table 1, and address ques-
tions that patients are most likely to have about lithium 
treatment. These points and specific questions should be 
discussed with each patient’s personal clinician prescrib-
ing lithium.
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